NCT05501886 2026-02-10
VIKTORIA-1
Celcuity Inc
Phase 3 Active not recruiting
Clinical Trials
9 trialsNCT05134922 2025-03-21
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009
Celcuity Inc
Available
NCT03911973 2024-06-07
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
Big Ten Cancer Research Consortium
Phase 1/2 Active not recruiting
NCT01920061 2022-09-13
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
Pfizer
Phase 1 Completed
NCT02684032 2022-07-27
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
Celcuity Inc
Phase 1 Completed
NCT02626507 2022-02-09
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
Hoffman Oncology
Phase 1 Unknown
NCT03698383 2021-02-18
Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer
Korean Cancer Study Group
Phase 2 Unknown
NCT03243331 2021-01-07
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
Indiana University
Phase 1 Completed
NCT03400254 2020-04-28
GLACIER
Abramson Cancer Center at Penn Medicine
Phase 1/2 Withdrawn